Brief: Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results
U.S. STOCKS ON THE MOVE-American Airlines, Netflix, Tesla
U.S. STOCKS ON THE MOVE-Amazon.com, US airlines, SolarEdge, Dynatronics
U.S. STOCKS ON THE MOVE-Invitae Corp, Aemetis, Discover Financial Services, Nvidia
U.S. STOCKS ON THE MOVE-Guardforce AI, Sphere Entertainment, Acurx Pharma
Acurx Pharma gains after ending colon drug mid-stage trial early
Acurx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals, Inc. Announces Pricing Of $4.0 Million Registered Direct Offering
Brief: Acurx Pharmaceuticals Inc Reports Q1 2023 Results And Provides Business Update
Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: FDA Accepts Interim Analysis Plan For Ongoing Phase 2b Ibezapolstat Clinical Trial
Acurx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Acurx Pharmaceuticals-Filed Protocol Amendment To Ind With FDA To Allow For Idmc To Review Interim Clinical Data From Ongoing Phase 2B Clinical Trial
Brief: Acurx Pharmaceuticals Reports Fourth Quarter Results
Acurx Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals To Discuss Fourth Quarter And Full Year 2022 Financial Results And Provide Business Update
Acurx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary